Search results
Results From The WOW.Com Content Network
Moderna's (NASDAQ: MRNA) sales are slowing down, and Moderna stock is going down -- a lot. The coronavirus vaccine maker's shares plunged 21.2% through 10:20 a.m. ET Monday after it updated ...
There was good news to share, but the market focused on a declining sales forecast and hammered the stock lower. Last November, Moderna said it expected 2024 revenue to land in a range between $3 ...
Moderna Inc (NASDAQ: MRNA) is trading lower Monday morning after the U.S. Food and Drug Administration delayed approval of the company's Emergency Use Authorization request for the use of its ...
Moderna's bad news The bad news is that Moderna will take longer than originally expected to get to the break-even point. Shareholders who have already been disappointed by declining sales in ...
Based on its share price, down 75% in the last three years, it's easy to write off Moderna (NASDAQ: MRNA) as a biotech that'll never recover its former glory -- which it built on the success of ...
In the presentation slides to the U.S. agency, Moderna Inc (NASDAQ:MRNA) shared safety set data, with a cut-off date of March 8, 2024, based on the median of 18.8 months of follow-up.
For premium support please call: 800-290-4726 more ways to reach us
For premium support please call: 800-290-4726 more ways to reach us